UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Nov

14

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Read More Share:linkedin| twitter| email

Sep

30

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

Read More Share:linkedin| twitter| email

Jun

12

UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

Read More Share:linkedin| twitter| email

May

06

Evolving Expectations for Arthritis Management

Read More Share:linkedin| twitter| email

Nov

09

Advancing Rheumatic Disease Treatment

Read More Share:linkedin| twitter| email

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Read More Share:linkedin| twitter| email

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Read More Share:linkedin| twitter| email

Nov

10

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Read More Share:linkedin| twitter| email

Nov

09

Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

Read More Share:linkedin| twitter| email

Nov

08

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)